Retroviral vector-mediated gene therapy for metabolic diseases: an update

Area of Science:

• Gene therapy
• Retroviral vector technology
• Hepatology

Background:

• Retroviral vectors have been explored for decades for liver gene therapy, initially using murine oncoretroviral vectors.
• Early attempts at treating inherited liver deficiencies with ex vivo or in vivo strategies showed limited success in animal models.

Purpose of the Study:

• To review the advancements and challenges in using retroviral vectors, particularly lentiviral vectors, for liver-directed gene therapy.
• To highlight key aspects limiting clinical development and discuss future directions.

Main Methods:

• Review of existing literature on retroviral vector applications in liver gene therapy.
• Focus on lentiviral vectors derived from HIV1 and their advantages.
• Analysis of challenges including insertional mutagenesis, cell cycle dependence, and immune responses.

Main Results:

• Lentiviral vectors offer an attractive option for liver gene therapy due to their ability to transduce non-dividing cells.
• Significant challenges remain, including the risk of insertional mutagenesis and potential immune reactions against transgenes.
• Ex vivo gene transfer strategies also present specific considerations for clinical application.

Conclusions:

• Lentiviral vectors represent a significant advancement in liver gene therapy, offering improved transduction efficiency.
• Overcoming hurdles such as insertional mutagenesis and immunogenicity is crucial for successful clinical translation.
• Future developments in cell and molecular biology hold promise for refining retroviral vector technology for therapeutic applications.